Clinical outcomes of vitamin D deficiency and supplementation in cancer patients

Nutrition Reviews

Volumn 71, Issue 9, 2013, Pages 611-621

  Teleni, Laisa ^a,b   Baker, Jacqueline ^c   Koczwara, Bogda ^d   Kimlin, Michael G ^a   Walpole, Euan ^b   Tsai, Kathy ^c   Isenring, Elizabeth A ^b,c  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

25 hydroxyvitamin D; Cancer; Cancer specific outcomes; Cholecalciferol; Vitamin D deficiency

Indexed keywords

CALCIDIOL; COLECALCIFEROL; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ARTICLE; BONE METABOLISM; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EVALUATION; COLORECTAL ADENOMA; COLORECTAL CANCER; DIETARY INTAKE; DISEASE FREE SURVIVAL; DRUG EFFICACY; HUMAN; LYMPH NODE METASTASIS; OSTEOLYSIS; OVERALL SURVIVAL; PROSTATE CANCER; RECURRENT DISEASE; SPINE FRACTURE; STOMACH CANCER; SYSTEMATIC REVIEW; TIME TO TREATMENT; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

25-HYDROXYVITAMIN D; CANCER; CANCER-SPECIFIC OUTCOMES; CHOLECALCIFEROL; VITAMIN D DEFICIENCY;

CALCIFEDIOL; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASMS; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84883464599     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/nure.12047     Document Type: Article

References (60)

1. Lappe JM, Travers-Gustafson D, Davies KM, etal. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85:1586-1591.
2. Chen P, Hu P, Xie D, etal. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat. 2010;121:469-477.
3. Purdue MP, Abnet CC, Peters U, etal. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst. 2008;100:796-804.
4. Lehtinen M, Hakama M, Luostarinen T, etal. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer. 2004;108:104-108.
5. Borradale D, Kimlin M. Vitamin D in health and disease: an insight into traditional functions and new roles for the "sunshine vitamin". Nutr Res. 2009;22:118-136.
6. Chang S, Graubard BI, Looker AC, etal. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst. 2007;99:1594-1602.
7. Nowson CA, Diamond TH, Pasco JA, etal. Vitamin D in Australia: issues and recommendations. Aust Fam Physician. 2004;33:133-138.
8. Zhang R, Naughton DP. Vitamin D in health and disease: current perspectives. Nutr J. 2010;9:65-78.
9. Palli D, Jansen EHJM, Lund E, etal. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ. 2010;340:b5500.
10. American Dietetic Association Scientific Affairs and Research. American Dietetic Association Evidence Analysis Manual. Edition IV. Chicago, IL: American Dietetic Association; 2005.
11. National Health and Medical Research Council, Australia. 2009. NHMRC levels of evidence and grades for recommendations for developers of guidelines. Canberra. Available at: http://www.nhmrc.gov.au/_files_nhmrc/file/guidelines/levels_grades05.pdf. Accessed February 2012.
12. Drake MT, Maurer MJ, Link BK, etal. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol. 2010;28:4191-4198.
13. Goodwin PJ, Ennis M, Pritchard KI, etal. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol. 2009;27:3757-3763.
14. Neuhouser ML, Bernstein L, Hollis BW, etal. Serum vitamin D and breast density in breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 2010;19:412-417.
15. Ng K, Sargent DJ, Goldberg RM, etal. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol. 2011;29:1599-1606.
16. Ng AC, Kumar SK, Rajkumar SV, etal. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol. 2009;84:397-400.
17. Jacot W, Pouderoux S, Thezenas S, etal. Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2012;134:709-717.
18. Fakih MG, Trump DL, Johnson CS, etal. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. Int J Colorectal Dis. 2009;24:219-224.
19. Mann GB, Kang YC, Brand C, etal. Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. J Clin Oncol. 2009;27:3605-3610.
20. Shanafelt TD, Drake MT, Maurer MJ, etal. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 2011;117:1492-1498.
21. Molica S, Digiesi G, Antenucci A, etal. Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL). Leuk Res. 2012;36:443-447.
22. Neuhouser ML, Sorensen B, Hollis BW, etal. Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr. 2008;88:133-139.
23. Bouvard B, Hoppe E, Soulie P, etal. High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy. Ann Oncol. 2012;23:1151-1156.
24. Choo CS, Mamedov A, Chung M, etal. Vitamin D insufficiency is common in patients with nonmetastatic prostate cancer. Nutr Res. 2011;31:21-26.
25. Heist RS, Zhou W, Wang Z, etal. Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:5596-5602.
26. Jacobs ET, Alberts DS, Benuzillo J, etal. Serum 25(OH)D levels, dietary intake of vitamin D, and colorectal adenoma recurrence. J Steroid Biochem Mol Biol. 2007;103:752-756.
27. Kim HJ, Lee YM, Ko BS, etal. Vitamin D deficiency is correlated with poor outcomes in patients with luminal-type breast cancer. Ann Surg Oncol. 2011;18:1830-1836.
28. Ren C, Qiu M-z, Wang D-s, etal. Prognostic effects of 25-hydroxyvitamin D levels in gastric cancer. J Transl Med. 2012;10:16.
29. Trump DL, Chadha MK, Sunga AY, etal. Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU Int. 2009;104:909-914.
30. Thomas X, Chelghoum Y, Fanari N, etal. Serum 25-hydroxyvitamin D levels are associated with prognosis in hematological malignancies. Hematology. 2011;16:278-283.
31. Tretli S, Hernes E, Berg JP, etal. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer. 2009;100:450-454.
32. Smith MR, McGovern FJ, Fallon MA, etal. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer. 2001;91:2238-2245.
33. Friedman CF, DeMichele A, Su HI, etal. Vitamin D deficiency in postmenopausal breast cancer survivors. J Womens Health. 2012;21:456-462.
34. Camacho P, Dayal A, Diaz J, etal. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. J Clin Oncol. 2008;26:5380-5385.
35. Meyer F, Liu G, Douville P, etal. Dietary vitamin D intake and serum 25-hydroxyvitamin D level in relation to disease outcomes in head and neck cancer patients. Int J Cancer. 2011;128:1741-1746.
36. Orell-Kotikangas H, Schwab U, Osterlund P, etal. High prevalence of vitamin D insufficiency in patients with head and neck cancer at diagnosis. Head Neck. 2012;34:1450-1455.
37. Napoli N, Vattikuti S, Ma C, etal. High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer. Breast J. 2010;16:609-616.
38. Vashi PG, Lammersfeld CA, Braun DP, etal. Serum 25-hydroxyvitamin D is inversely associated with body mass index in cancer. Nutr J. 2011;10:51.
39. Waltman NL, Ott CD, Twiss JJ, etal. Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy. Cancer Nurs. 2009;32:143-150.
40. Wang-Gillam A, Miles DA, Hutchins LF. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates. Oncologist. 2008;13:821-827.
41. Willemse PM, Hamdy NAT, Van Wulften L, etal. Prevalence of vertebral fractures independent of BMD and anticancer treatment in patients with testicular germ cell tumors. J Clin Endocrinol Metab. 2010;95:4933-4942.
42. Amir E, Simmons C, Freedman O, etal. A phase 2 trial exploring the effects of high-dose (10, 000IU/day) vitamin D3 in breast cancer patients with bone metastases. Cancer. 2010;116:284-291.
43. Khan QJ, Reddy PS, Kimler BF, etal. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat. 2010;119:111-118.
44. Nogues X, Servitja S, Pena MJ, etal. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. Maturitas. 2010;66:291-297.
45. Peppone LJ, Huston AJ, Reid ME, etal. The effect of various vitamin D supplementation regimens in breast cancer patients. Breast Cancer Res Treat. 2011;127:171-177.
46. Crew KD, Shane E, Cremers S, etal. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol. 2009;27:2151-2156.
47. Prieto-Alhambra D, Javaid MK, Servitja S, etal. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat. 2011;125:869-878.
48. Vashi PG, Trukova K, Lammersfeld CA, etal. Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology. Nutr J. 2010;9:60.
49. World Health Organisation. Vitamin D and Cancer: IARC Working Groups Report, Vol. 5. Lyon, France: International Agency for Research on Cancer; 2008.
50. Holick MF. Medical progress: vitamin D deficiency. N Engl J Med. 2007;357:266-281.
51. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19:73-78.
52. Nowak M, Harrison SL, Buettner PG, etal. Vitamin D status of adults from tropical Australia determined using two different laboratory assays: implications for public health messages. Photochem Photobiol. 2011;87:935-943.
53. Buttigliero C, Monagheddu C, Petroni P, etal. Prognostic role of vitamin D status and efficacy of vitamin D supplementation in cancer patients: a systematic review. Oncologist. 2011;16:1215-1227.
54. Gallicchio L, Shu XO, Virtamo J, etal. Correlates of circulating 25-hydroxyvitamin D: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172:21-35.
55. Lagunova Z, Porojnicu AC, Lindberg F, etal. The dependency of vitamin D status on body mass index, gender, age and season. Anticancer Res. 2009;29:3713-3720.
56. Bischof M, Heinze G, Vierhapper H. Vitamin D status and its relation to age and body mass index. Horm Res. 2006;66:211-215.
57. Vieth R. Vitamin D and cancer mini-symposium: the risk of additional vitamin D. Ann Epidemiol. 2009;19:441-445.
58. National Cancer Institute. 2010. Fact Sheet: Vitamin D and cancer prevention: Strengths and limits of the evidence. Bethesda, MD, National Institutes of Health. Available at: http://www.cancer.gov/cancertopics/factsheet/prevention/vitamin-D. Accessed February 2012.
59. Bjelakovic G, Gluud Lise L, Nikolova D, etal. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev. 2009;doi: 10.1002/14651858.CD007469.
60. Ross C, Taylor CL, Yaktine AL, etal., eds. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.